StockData

Lensar vs TELA Bio

LNSR and TELA side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How LNSR and TELA compare

Lensar is the larger company, worth 1.8 times as much as TELA Bio ($60.3M against $34.2M).

TELA Bio grew revenue faster over the last twelve months (6.1% versus 3.3% for Lensar).

Lensar keeps more of each dollar of sales as profit, with a net margin of 57.6% compared with −51.5% at TELA Bio.

Lensar scores higher on the StockData Score (8 against 5 for TELA Bio), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricLNSRTELA
Size and price
Market cap$60.3M$34.2M
Share price$4.91$0.762
Change, 1 year−51.4%−23.7%
Change, 5 years−30.0%−93.8%
Beta (5Y)1.612.04
Employees150218
StockData Score
Total score8 (better)5
Valuation score2 (better)1
Growth score22
Performance score2 (better)1
Health score2 (better)1
Dividend score00
Valuation
P/S1.0×0.4× (better)
P/B4.0×–
FCF yield–−92.4%
Fair value$6.31–
Margin of safety22.2%–
Growth
Revenue growth (TTM)3.3%6.1% (better)
Revenue growth, 5Y average17.2%34.5% (better)
Profitability
Gross margin48.3%67.8% (better)
Operating margin−13.5% (better)−42.6%
Net margin57.6% (better)−51.5%
FCF margin–−39.6%
Return on invested capital–−212%
Financial health
Debt / equity0.25–
Interest coverage–−4.9×
Current ratio2.392.99 (better)
Altman Z-score−0.93 (better)−9.41
Piotroski F-score33
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions36.0%70.5%
Held by insiders–41.0%
Insider net buying, 12 months–$186K
Short interest, % of float–2.2%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.